RJMPDRN REC is a vegan-certified recombinant PDRN produced through a patented biological synthesis platform using engineered ...

On February 20, 2026, in REGENXBIO Inc. et al. v. Sarepta Therapeutics Inc., et al., No. 2024-1408, the Federal Circuit reversed a district court decision which held that claims covering a cultured ...

The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...

Recombinant DNA Infectious organisms and viruses (like parasites, bacteria, fungi, prions, and viroids) Biologically active agents (like toxins, allergens, and venoms) Human blood and blood products ...

The AI2Health cluster of the Ken Kennedy Institute and the Synthetic Biology Institute at Rice University hosted a debriefing and collaborative discussion session on the Spirit of Asilomar summit June ...

Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

The DNA synthesis market offers significant growth opportunities driven by tailored therapies, DNA-based research, and diagnostics. Key market prospects include advancements in enzymatic synthesis, ...